title: Slow metabolic deterioration towards diabetes in islet cell antibody positive patients with autoimmune polyendocrine disease.
abstract: We studied metabolic progression to IDDM in a cohort of adults who are ICA-positive and have associated autoimmune endocrine disease or circulating organ-specific autoantibodies (the Polyendocrine Study). Of the 186 individuals recruited 27 developed overt diabetes after a median follow-up of 4.5 years (range 0.4-12). Of these, eight patients did not require insulin treatment until at least 6 months after clinical diagnosis, with an interval of 1.8 years (1.2-5.7). An IVGTT was performed in 38 subjects and 23 had sequential studies. Of the initial 38 subjects six developed diabetes and only three showed a loss of FPIR to glucose (below the first percentile of a normal control group) before clinical onset of the disease. An additional three subjects showed a loss of the FPIR, and all still have normal glucose tolerance after median follow-up of 28 months (22-95). A "whole" or "mixed" pattern of islet cell staining was found in five of the six patients who developed diabetes and antibodies against an islet 37 k-antigen were detectable in four patients, all of whom required insulin soon after diagnosis. A beta-cell "selective" ICA staining pattern was seen in 14 of 17 subjects who did not develop diabetes and the "mixed" pattern in only three. None of this group had detectable 37 k-antibodies. We conclude that metabolic deterioration is slow in polyendocrine patients, and that the IVGTT has less prognostic significance in this group than in first degree relatives of patients with IDDM.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Immunology, London Hospital Medical College, UK.
authors.forename: R
authors.initials: R
authors.lastname: Wagner
authors.forename: S
authors.initials: S
authors.lastname: Genovese
authors.forename: E
authors.initials: E
authors.lastname: Bosi
authors.forename: F
authors.initials: F
authors.lastname: Becker
authors.forename: P J
authors.initials: PJ
authors.lastname: Bingley
authors.forename: E
authors.initials: E
authors.lastname: Bonifacio
authors.forename: K A
authors.initials: KA
authors.lastname: Miles
authors.forename: M R
authors.initials: MR
authors.lastname: Christie
authors.forename: G F
authors.initials: GF
authors.lastname: Bottazzo
authors.forename: E A
authors.initials: EA
authors.lastname: Gale
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001323:Autoantibodies / Q000032:analysis*; D001786:Blood Glucose / Q000032:analysis; D003922:Diabetes Mellitus, Type 1 / Q000209:etiology / Q000378:metabolism*; D005260:Female; D005455:Fluorescent Antibody Technique; D005951:Glucose Tolerance Test; D005968:Glutamate Decarboxylase / Q000276:immunology; D006801:Humans; D007330:Insulin Antibodies / Q000032:analysis; D007515:Islets of Langerhans / Q000276:immunology / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D016884:Polyendocrinopathies, Autoimmune / Q000150:complications / Q000378:metabolism*
chemical_list: D001323:Autoantibodies; D001786:Blood Glucose; D007330:Insulin Antibodies; D005968:Glutamate Decarboxylase